|
Market Closed -
London S.E.
16:35:11 01/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 1,571.00 GBX | -2.90% |
|
-3.32% | +1.35% |
| 09-24 | Hikma Pharmaceuticals appoints ViiV's Rebecca Hall as CFO | AN |
| 09-24 | Hikma Pharmaceuticals Appoints CFO | MT |
| Market Cap | 4.34B 3.85B 3.6B 3.28B 6.18B 418B 6.26B 43.58B 16.87B 213B 16.28B 15.93B 683B | P/E 2026 * |
11.3x | P/E 2027 * | 10.1x |
|---|---|---|---|---|---|
| Enterprise Value | 5.82B 5.17B 4.84B 4.41B 8.3B 560B 8.41B 58.5B 22.64B 285B 21.86B 21.38B 917B | EV / Sales 2026 * |
1.68x | EV / Sales 2027 * | 1.57x |
| Free-Float |
63.16% | Yield 2026 * |
4.16% | Yield 2027 * | 4.41% |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| HIK | Delayed | |
CBOE
| HIK | Real-time | |
|
OTC Markets
| HKMPF | Delayed | |
|
Mexican S.E.
| HIK N | End-of-day quote | |
|
Boerse Muenchen
| H5P | Real-time | |
|
Tradegate
| H5P | Real-time | |
|
Deutsche Boerse AG
| H5P | Delayed | |
|
Börse Stuttgart
| H5P | Delayed |
Last Transcript: Hikma Pharmaceuticals PLC
| 1 day | -2.90% | ||
| 1 week | -3.32% | ||
| Current month | -2.90% | ||
| 1 month | -2.72% | ||
| 3 months | +3.08% | ||
| 6 months | +22.07% | ||
| Current year | +1.35% |
| 1 week | 1,571 |  | 1,635 |
| 1 month | 1,483.69 | | 1,638 |
| Current year | 1,187 | | 1,762 |
| 1 year | 1,187 | | 1,865 |
| 3 years | 1,187 | | 2,360 |
| 5 years | 1,174.5 | | 2,496 |
| 10 years | 814.2 | | 2,768 |
| Manager | Title | Age | Since |
|---|---|---|---|
Said Darwazah
CEO | Chief Executive Officer | 69 | 30/11/2025 |
Areb Kurdi
DFI | Director of Finance/CFO | - | 25/02/2026 |
| Chief Tech/Sci/R&D Officer | 64 | 25/02/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 69 | 13/10/2005 | |
Khalid Nabilsi
BRD | Director/Board Member | 54 | 14/12/2025 |
Said Darwazah
CHM | Chairman | 69 | 14/05/2014 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 01/06/26 | Sell | Investor Relations Manager | -26,558 | 0.0124% | ||
| 01/06/26 | Exercice | Director | 72,763 | 0.0339% | ||
| 01/06/26 | Exercice | Director | 20,650 | 0.0096% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.90% | -3.32% | -12.48% | -24.76% | 4.52B | |
| -0.62% | -2.71% | +39.30% | +114.07% | 1,031B | |
| -2.30% | -4.44% | +39.03% | +66.07% | 638B | |
| -0.63% | -1.96% | +6.36% | +74.38% | 462B | |
| -1.03% | -2.82% | +59.56% | +39.69% | 359B | |
| -0.03% | -3.96% | +23.63% | +39.35% | 335B | |
| -1.58% | -0.76% | +13.50% | +25.77% | 273B | |
| -2.02% | -2.97% | -3.25% | +8.38% | 253B | |
| -3.38% | +0.30% | +36.44% | +51.54% | 228B | |
| -1.04% | -1.46% | +32.70% | +96.82% | 185B | |
| Average | -1.55% | -1.75% | +23.48% | +49.13% | 376.84B | |
| Weighted average by Cap. | -1.25% | -1.90% | +30.46% | +69.07% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.46B 3.07B 2.87B 2.62B 4.93B 333B 5B 34.77B 13.46B 170B 12.99B 12.71B 545B | 3.6B 3.2B 2.99B 2.73B 5.13B 347B 5.2B 36.19B 14.01B 177B 13.52B 13.23B 567B |
| Net income | 412M 366M 342M 312M 587M 39.69B 595M 4.14B 1.6B 20.21B 1.55B 1.51B 64.92B | 453M 403M 377M 343M 646M 43.66B 655M 4.56B 1.76B 22.23B 1.7B 1.67B 71.41B |
| Net Debt | 1.48B 1.32B 1.23B 1.12B 2.12B 143B 2.14B 14.92B 5.77B 72.79B 5.57B 5.45B 234B | 1.31B 1.16B 1.09B 992M 1.87B 126B 1.89B 13.17B 5.1B 64.26B 4.92B 4.81B 206B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/10/26 | GBX 1,571.00 | -2.90% | 837,999 |
| 30/09/26 | GBX 1,618.00 | +0.56% | 582,871 |
| 29/09/26 | GBX 1,609.00 | +1.07% | 447,427 |
| 28/09/26 | GBX 1,592.00 | +0.13% | 409,351 |
| 25/09/26 | GBX 1,590.00 | -2.15% | 264,760 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- HIK Stock
Select your edition
All financial news and data tailored to specific country editions
